Cite
68 Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy.
MLA
Shagera, Qaid Ahmed, et al. “68 Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 63, no. 8, Aug. 2022, pp. 1191–98. EBSCOhost, https://doi.org/10.2967/jnumed.121.263006.
APA
Shagera, Q. A., Artigas, C., Karfis, I., Critchi, G., Chanza, N. M., Sideris, S., Peltier, A., Paesmans, M., Gil, T., & Flamen, P. (2022). 68 Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 63(8), 1191–1198. https://doi.org/10.2967/jnumed.121.263006
Chicago
Shagera, Qaid Ahmed, Carlos Artigas, Ioannis Karfis, Gabriela Critchi, Nieves Martinez Chanza, Spyridon Sideris, Alexandre Peltier, Marianne Paesmans, Thierry Gil, and Patrick Flamen. 2022. “68 Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 63 (8): 1191–98. doi:10.2967/jnumed.121.263006.